⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butanedione SCHEMBL9849141 | 0.78 | TSHR (0.41) | — | |
| SCHEMBL6130994 | 0.77 | KDM4E (0.48) | — | |
| SCHEMBL404097 | 0.77 | — | — | |
| SCHEMBL170514 | 0.76 | — | — | |
| SCHEMBL4761576 | 0.75 | — | — | |
| SCHEMBL27383468 | 0.75 | KDM4E (0.68) | — | |
| SCHEMBL23462877 | 0.73 | KDM4E (0.52) | — | |
| SCHEMBL12606603 | 0.73 | ADH1B (0.32) | — | |
| SCHEMBL22811174 | 0.73 | KDM4E (0.73) | — | |
| SCHEMBL14910879 | 0.73 | KDM4E (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-20170229735-A1 | GEL POLYMER ELECTROLYTE AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2017-08-10 | — | — | US | disclosed |
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-05-21 | — | — | US | disclosed |
| EP-2637665-B1 | DEXAMETHASONE COMBINATION THERAPY | UNIV TEXAS (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2849756-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | Novartis AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| CN-104349779-A | Dosage regimen for a pi-3 kinase inhibitor | NOVARTIS AG | 2015-02-11 | — | — | CN | disclosed |
| US-20140213583-A1 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| EP-2750670-A1 | PI3K INHIBITOR FOR USE IN THE TREATMENT OF BONE CANCER OR FOR PREVENTING METASTATIC DISSEMINATION PRIMARY CANCER CELLS INTO THE BONE | Novartis AG (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20130310352-A1 | DEXAMETHASONE COMBINATION THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-11-21 | — | — | US | disclosed |
| EP-1575940-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1537099-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004060308-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |